PDE4在大脑中的分布及其在神经退行性疾病中的作用

摘要/Abstract

摘要：

第二信使环磷酸腺苷（cyclic adenosine monophosphate，cAMP）参与多种神经退行性疾病的发生发展，如阿尔兹海默病、帕金森病以及亨廷顿病。但是对cAMP进行直接调控具有一定的难度，因此靶向调控cAMP的水解酶有望成为改善神经退行性疾病的新策略。磷酸二酯酶4（phosphodiesterases， PDE4）是特异性催化cAMP的酶，已被证实在多种神经退行性疾病的发展中具有重要作用。研究并开发靶向PDE4的药物将有助于神经退行性疾病的治疗。本文综述了PDE4的特性和功能，回顾了其在神经退行性疾病中的作用及研究进展，并对其在神经退行性疾病中的潜在治疗作用作出展望。

关键词:PDE4,阿尔茨海默病,帕金森病,亨廷顿病,神经退行性疾病

Abstract:

Aberrant changes in the second messenger cyclic adenosine monophosphate （cAMP） are involved in the development of several neurodegenerative diseases such as Alzheimer's disease， Parkinson's disease and Huntington's disease. However， it is difficult to directly regulate cAMP signal. Therefore， targeted regulation of cAMP hydrolase is expected to be a new strategy to improve neurodegenerative diseases. Phosphodiesterase 4（PDE4）， an enzyme that specifically catalyzes cAMP， has been shown to have an important role in the development of a variety of neurodegenerative diseases. Research into drugs targeting PDE4 will help in the treatment of neurodegenerative diseases. In this paper， we will describe the characteristics and function of PDE4， review its role and research into progress in neurodegenerative diseases and future development trend of its potential therapeutic effect in neurodegenerative diseases.

Key words:phosphodiesterase 4,Alzheimer's disease,Parkinson disease,Huntington's disease,neurodegenerative diseases

杨寒冰, 史佳玮, 侯越, 张棋炜, 于海洋, 周延萌. PDE4在大脑中的分布及其在神经退行性疾病中的作用[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(3): 186-190.

Hanbing YANG, Jiawei SHI, Yue HOU, Qiwei ZHANG, Haiyang YU, Yanmeng ZHOU. Distribution of PDE4 in the brain and its role in neurodegenerative diseases[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(3): 186-190.

参考文献62

1	Oboudiyat C， Glazer H， Seifan A， et al. Alzheimer's disease［J］. Semin Neurol， 2013， 33（4）： 313.
2	Plath N， Lerdrup L， Larsen PH， et al. Can small molecules provide truly effective enhancement of cognition？ Current achievements and future directions［J］. Expert Opin Investig Drugs， 2011， 20（6）： 795.
3	Gurney ME， D'Amato EC， Burgin AB. Phosphodiesterase-4 （PDE4） molecular pharmacology and Alzheimer's disease［J］. Neurotherapeutics， 2015， 12（1）： 49.
4	Blokland A， Menniti FS， Prickaerts J. PDE inhibition and cognition enhancement［J］. Expert Opin Ther Pat， 2012， 22（4）： 349.
5	Ghavami A， Hirst WD， Novak TJ. Selective phosphodiesterase （PDE）-4 inhibitors： a novel approach to treating memory deficit？［J］. Drugs R D， 2006， 7（2）： 63.
6	Kleppisch T. Phosphodiesterases in the central nervous system［J］. Handb Exp Pharmacol， 2009， 191： 71.
7	Menniti FS， Faraci WS， Schmidt CJ. Phosphodiesterases in the CNS： targets for drug development［J］. Nat Rev Drug Discov， 2006， 5（8）： 660.
8	Xu Y， Zhang HT， O'Donnell JM. Phosphodiesterases in the central nervous system： implications in mood and cognitive disorders［J］. Handb Exp Pharmacol， 2011， 204： 447.
9	Pérez-Torres S， Miró X， Palacios JM， et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and［3H］rolipram binding autoradiography. Comparison with monkey and rat brain［J］. J Chem Neuroanat， 2000， 20（3/4）： 349.
10	Johansson EM， Reyes-Irisarri E， Mengod G. Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain［J］. Neurosci Lett， 2012， 525（1）： 1.
11	Fatemi SH， Reutiman TJ， Folsom TD， et al. Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder［J］. Psychiatr Genet， 2008， 18（6）： 282.
12	Braun NN， Reutiman TJ， Lee S， et al. Expression of phosphodiesterase 4 is altered in the brains of subjects with autism［J］. Neuroreport， 2007， 18（17）： 1841.
13	Jin SL， Goya S， Nakae S， et al. Phosphodiesterase 4B is essential for T_H2-cell function and development of airway hyperresponsiveness in allergic asthma［J］. J Allergy Clin Immunol， 2010， 126（6）： 1252.
14	Reyes-Irisarri E， Pérez-Torres S， Miró X， et al. Differential distribution of PDE4B splice variant mRNAs in rat brain and the effects of systemic administration of LPS in their expression［J］. Synapse， 2008， 62（1）： 74.
15	Ahmed T， Frey JU. Expression of the specific type Ⅳ phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of ratsin vitro［J］. Neuroscience， 2003， 117（3）： 627.
16	Ahmed T， Frey JU. Phosphodiesterase 4B （PDE4B） and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-term potentiationin vitro［J］. Brain Res， 2005， 1041（2）： 212.
17	Ahmed T， Frey S， Frey JU. Regulation of the phosphodiesterase PDE4B3-isotype during long-term potentiation in the area dentatain vivo［J］. Neuroscience， 2004， 124（4）： 857.
18	Zhang HT， Huang Y， Masood A， et al. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B （PDE4B）［J］. Neuropsychopharmacology， 2008， 33（7）： 1611.
19	Jin SL， Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses［J］. Proc Natl Acad Sci U S A， 2002， 99（11）： 7628.
20	Rubio-Perez JM， Morillas-Ruiz JM. A review： inflammatory process in Alzheimer's disease， role of cytokines［J］. ScientificWorldJournal， 2012， 2012： 756357.
21	Sebastiani G， Morissette C， Lagacé C， et al. The cAMP-specific phosphodiesterase 4B mediates Aβ-induced microglial activation［J］. Neurobiol Aging， 2006， 27（5）： 691.
22	Miró X， Pérez-Torres S， Puigdomènech P， et al. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization［J］. Synapse， 2002， 45（4）： 259.
23	Rutten K， Misner DL， Works M， et al. Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout （PDE4D） mice［J］. Eur J Neurosci， 2008， 28（3）： 625.
24	Li YF， Cheng YF， Huang Y， et al. Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling［J］. J Neurosci， 2011， 31（1）： 172.
25	Burgin AB， Magnusson OT， Singh J， et al. Design of phosphodiesterase 4D （PDE4D） allosteric modulators for enhancing cognition with improved safety［J］. Nat Biotechnol， 2010， 28（1）： 63.
26	Bruno O， Fedele E， Prickaerts J， et al. GEBR-7b， a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses［J］. Br J Pharmacol， 2011， 164（8）： 2054.
27	Wang ZZ， Zhang Y， Liu YQ， et al. RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects［J］. Br J Pharmacol， 2013， 168（4）： 1001.
28	Schaefer TL， Braun AA， Amos-Kroohs RM， et al. A new model of Pde4d deficiency： genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects［J］. Genes Brain Behav， 2012， 11（5）： 614.
29	Lonze BE， Ginty DD. Function and regulation of CREB family transcription factors in the nervous system［J］. Neuron， 2002， 35（4）： 605.
30	Ota KT， Pierre VJ， Ploski JE， et al. The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase［J］. Learn Mem， 2008， 15（10）： 792.
31	Purcell AL， Sharma SK， Bagnall MW， et al. Activation of a tyrosine kinase-MAPK cascade enhances the induction of long-term synaptic facilitation and long-term memory in Aplysia［J］. Neuron， 2003， 37（3）： 473.
32	Miyamoto E. Molecular mechanism of neuronal plasticity： induction and maintenance of long-term potentiation in the hippocampus［J］. J Pharmacol Sci， 2006， 100（5）： 433.
33	Arancio O， Antonova I， Gambaryan S， et al. Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation［J］. J Neurosci， 2001， 21（1）： 143.
34	Li YF， Huang Y， Amsdell SL， et al. Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus［J］. Neuropsychopharmacology， 2009， 34（11）： 2404.
35	Adams JP， Sweatt JD. Molecular psychology： roles for the ERK MAP kinase cascade in memory［J］. Annu Rev Pharmacol Toxicol， 2002， 42： 135.
36	Hoffmann R， Baillie GS， MacKenzie SJ， et al. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579［J］. EMBO J， 1999， 18（4）： 893.
37	Stork PJ， Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation［J］. Trends Cell Biol， 2002， 12（6）： 258.
38	Gao Y， Deng K， Hou J， et al. Activated CREB is sufficient to overcome inhibitors in myelin and promote spinal axon regenerationin vivo［J］. Neuron， 2004， 44（4）： 609.
39	Valera E， Sánchez-Martín FJ， Ferrer-Montiel AV， et al. NMDA-induced neuroprotection in hippocampal neurons is mediated through the protein kinase A and CREB （cAMP-response element-binding protein） pathway［J］. Neurochem Int， 2008， 53（5）： 148.
40	Zhang HT， Zhao Y， Huang Y， et al. Inhibition of the phosphodiesterase 4 （PDE4） enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus［J］. Neuropsychopharmacology， 2004， 29（8）： 1432.
41	Navakkode S， Sajikumar S， Frey JU. Mitogen-activated protein kinase-mediated reinforcement of hippocampal early long-term depression by the type Ⅳ-specific phosphodiesterase inhibitor rolipram and its effect on synaptic tagging［J］. J Neurosci， 2005， 25（46）： 10664.
42	Gouras GK， Olsson TT， Hansson O. β-amyloid peptides and amyloid plaques in Alzheimer's disease［J］. Neurotherapeutics， 2015， 12（1）： 3.
43	Pooler AM， Noble W， Hanger DP. A role for tau at the synapse in Alzheimer's disease pathogenesis［J］. Neuropharmacology， 2014， 76 Pt A： 1.
44	Gao Y， Tan L， Yu JT， et al. Tau in Alzheimer's disease： mechanisms and therapeutic strategies［J］. Curr Alzheimer Res， 2018， 15（3）： 283.
45	Toledo JB， Zetterberg H， Van Harten AC， et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects［J］. Brain， 2015， 138（Pt 9）： 2701.
46	刘俊乐，张良成. 线粒体功能障碍及炎症与衰老的相关关系［J］. 中华老年多器官疾病杂志， 2019， 18（6）： 469.
47	Pérez-Torres S， Cortés R， Tolnay M， et al. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization［J］. Exp Neurol， 2003， 182（2）： 322.
48	Liang Z， Liu F， Grundke-Iqbal I， et al. Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain［J］. J Neurochem， 2007， 103（6）： 2462.
49	Gong B， Vitolo OV， Trinchese F， et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment［J］. J Clin Invest， 2004， 114（11）： 1624.
50	Xu B， Qin Y， Li D， et al. Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2/HO-1 pathway［J］. Redox Biol， 2020， 28： 101342.
51	Sutcliffe JS， Beaumont V， Watson JM， et al. Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys （Macaca fascicularis）［J］. PLoS One， 2014， 9（7）： e102449.
52	Chidambaram SB， Bhat A， Ray B， et al. Cocoa beans improve mitochondrial biogenesis via PPARγ/PGC1α dependent signalling pathway in MPP⁺intoxicated human neuroblastoma cells （SH-SY5Y）［J］. Nutr Neurosci， 2020， 23（6）： 471.
53	Heckman PRA， Van Duinen MA， Bollen EPP， et al. Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning： clinical implications［J］. Int J Neuropsychopharmacol， 2016， 19（10）： pyw030.
54	Zhong J， Yu H， Huang C， et al. Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP⁺-induced decline of mitochondrial membrane potential and oxidative stress［J］. Redox Biol， 2018， 16： 47.
55	Hulley P， Hartikka J， Abdel'Al S， et al. Inhibitors of type Ⅳ phosphodiesterases reduce the toxicity of MPTP in substantia nigra neuronsin vivo［J］. Eur J Neurosci， 1995， 7（12）： 2431.
56	Nishi A， Kuroiwa M， Miller DB， et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum［J］. J Neurosci， 2008， 28（42）： 10460.
57	Takuma K， Lee E， Enomoto R， et al. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in anin vitroreperfusion model［J］. Br J Pharmacol， 2001， 133（6）： 841.
58	Hickey MA， Chesselet MF. Apoptosis in Huntington's disease［J］. Prog Neuropsychopharmacol Biol Psychiatry， 2003， 27（2）： 255.
59	Tanaka M， Ishizuka K， Nekooki-Machida Y， et al. Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease［J］. J Clin Invest， 2017， 127（4）： 1438.
60	Zuccato C， Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease［J］. Prog Neurobiol， 2007， 81（5/6）： 294.
61	Giralt A， Saavedra A， Carretón O， et al. Increased PKA signaling disrupts recognition memory and spatial memory： role in Huntington's disease［J］. Hum Mol Genet， 2011， 20（21）： 4232.
62	DeMarch Z， Giampà C， Patassini S， et al. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease［J］. Neurobiol Dis， 2008， 30（3）： 375.

[1]	董柏萍, 王永生, 吕静静, 韩燕珍, 袁锁伟, 梁永, 毛蕾蕾.基于微小RNA‐146a探究川陈皮素对帕金森病模型的神经保护作用[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(4): 254-259.
[2]	郑天成, 郭俊, 孙宪昌.RIP1/RIP3介导的程序性坏死在LPS诱导的多巴胺神经元损伤中的作用[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(7): 481-488.
[3]	王倩, 肖洪玲, 肖云久, 陈美玲, 张贻婷.预见性护理对阿尔茨海默病患者效果的Meta分析[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(7): 534-539.
[4]	冯春玲, 史革鑫, 郭硕, 王蕾.枸杞子干预阿尔茨海默病作用机制的网络药理学研究[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(12): 883-888.